San Mateo, CA, United States of America

Antonio Feula

This inventor holds 1 USPTO granted patent. Top assignee: Asteroid Therapeutics. Active years: 2025.


% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Antonio Feula: Innovator in Steroidal Compositions

Introduction

Antonio Feula is a notable inventor based in San Mateo, CA (US). He has made significant contributions to the field of medicinal chemistry, particularly in the development of steroidal compositions aimed at treating lipogenic cancers. His innovative work has led to the filing of a patent that showcases his expertise and dedication to advancing medical treatments.

Latest Patents

Antonio Feula holds a patent for "Steroidal compositions and methods of treating lipogenic cancers." This invention describes novel steroidal compounds, compositions containing the same, and methods of using these compounds as SREBP inhibitors, LXR agonists, or as dual modulators of SREBP and LXR. The goal of this invention is to provide effective treatments for diseases mediated by SREBP and/or LXR.

Career Highlights

Antonio Feula is currently associated with Asteroid Therapeutics, where he continues to work on innovative solutions in the pharmaceutical industry. His career is marked by a commitment to research and development, focusing on the intersection of chemistry and medicine.

Collaborations

Antonio collaborates with talented individuals such as Francesco Gerald Salituro and Ryan Edward Stites. These partnerships enhance the research environment and contribute to the advancement of their shared goals in medical innovation.

Conclusion

Antonio Feula's work in steroidal compositions represents a significant advancement in the treatment of lipogenic cancers. His innovative spirit and collaborative efforts continue to drive progress in the field of medicinal chemistry.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…